160,610 Shares in Amneal Pharmaceuticals, Inc. $AMRX Purchased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. acquired a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 160,610 shares of the company’s stock, valued at approximately $1,608,000.

A number of other institutional investors have also bought and sold shares of AMRX. Assenagon Asset Management S.A. boosted its holdings in shares of Amneal Pharmaceuticals by 187.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,150,041 shares of the company’s stock worth $21,522,000 after purchasing an additional 1,401,190 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in Amneal Pharmaceuticals by 1,440.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company’s stock worth $11,790,000 after buying an additional 1,062,045 shares in the last quarter. Rubric Capital Management LP boosted its stake in Amneal Pharmaceuticals by 9.1% during the second quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company’s stock worth $94,737,000 after buying an additional 974,355 shares during the last quarter. BlackBarn Capital Partners LP grew its holdings in Amneal Pharmaceuticals by 19.6% in the 2nd quarter. BlackBarn Capital Partners LP now owns 3,446,570 shares of the company’s stock valued at $27,883,000 after buying an additional 564,916 shares in the last quarter. Finally, Nantahala Capital Management LLC grew its holdings in Amneal Pharmaceuticals by 14.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after buying an additional 558,877 shares in the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Trading Down 4.7%

Shares of NASDAQ:AMRX opened at $13.81 on Friday. The company has a market capitalization of $4.34 billion, a price-to-earnings ratio of 60.05 and a beta of 1.36. Amneal Pharmaceuticals, Inc. has a 12-month low of $6.68 and a 12-month high of $15.42. The business has a 50-day moving average price of $13.74 and a 200 day moving average price of $11.74.

More Amneal Pharmaceuticals News

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q4 and full‑year results showed clear improvement: Q4 adjusted EPS of $0.21 beat consensus and Q4 revenue was $814M; full‑year 2025 revenue rose to $3.02B with GAAP net income of $72M and adjusted EBITDA growth. These results underline recovering profitability and stronger specialty sales. Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Company issued 2026 adjusted diluted EPS guidance of $0.93–$1.03 (above the cited consensus ~$0.92), signaling management confidence in continued margin and earnings improvement. Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Growth drivers: Specialty products (CREXONT®, UNITHROID®, new branded launches such as BREKIYA®) and AvKARE distribution gains are cited by management as the primary growth engines — supportive long‑term but timing/launch execution will matter. Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst/institution activity: recent coverage includes overweight views and price targets around the mid‑teens; institutional flows are mixed per data aggregators — watch for any analyst reactions to the new guidance. QuiverQuant Summary
• Negative Sentiment: Revenue guidance is effectively in a narrow band (~$3.05–$3.15B per the press release; another bulletin cited $3.10–$3.20B), which is around or a touch below some Street revenue expectations — investors may mark the stock down on any perception of decelerating top‑line growth. Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Leverage remains a material risk: gross debt increased after refinancing and net debt was reported near ~$2.4B with net leverage around ~3.5x on 2025 adjusted EBITDA — higher interest/credit risks could cap valuation until deleveraging progresses. QuiverQuant Summary
• Negative Sentiment: Short‑interest data is noisy and recently volatile in third‑party feeds (one snapshot shows ~10.6M shares short, ~4.1% of float); elevated short positions and data inconsistencies can amplify intraday moves and volatility. MarketBeat AMRX page

Wall Street Analyst Weigh In

Several research firms have recently commented on AMRX. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Truist Financial set a $15.00 price objective on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 7th. Finally, Barclays initiated coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $15.00 target price on the stock. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $13.80.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.